Board of Directors

_W8A8537LEVFF

Andrew Kay

Born 1955. Chairman of the Board since 2015. Member of the audit committee.

  • Education: BPharm Hons, Nottingham University.
  • Other current assignments: Chairman of Blueberry Therapeutics, director of Amulet Consulting and senior advisor of HealthCap.
  • Previous assignments (last five years): CEO of Algeta ASA.
  • Position: Independent of the Company, executive management and major shareholders.
  • Holdings in the Company: 7,088 shares,  255,000 stock options and 24,000 performance shares Board LTIP 2016.

Dina Chaya

Dina Chaya

Born 1971. Board Member since 2015.

  • Education: CFA charterholder, CFA Institute and BSc in natural sciences tripos, Cambridge University and MSc in development biology and PhD in molecular and cellular biology of development, Paris VI University.
  • Other current assignments: Partner of NeoMed Management (Jersey) Limited. Board member of Oxular Ltd, TopiVert Ltd and TopiVert Pharma Ltd.
  • Previous assignments (last five years): None.
  • Position: Independent of the Company, executive management and major shareholders.
  • Holdings in the Company: None.

_W8A8505LEVFF

Genghis Lloyd-Harris

Born 1957. Board Member since 2014. Chairman of audit committee and member of the remuneration committee.

  • Education: MBA, Harvard University, PhD in pharmacology, University of Melbourne, MB ChB Hons in medicine and BSc Hons in biochemistry, University of Liverpool.
  • Other current assignments: Board member of Abingworth LLP, Abingworth Avillion Blocker Limited, Avillion LLP and Gensight Biologics SA.
  • Previous assignments (last five years): Board member of Syntaxin Limited.
  • Position: Independent of the Company and executive management. Dependent to major shareholders.
  • Holdings in the Company: 90,000 shares.

_W8A8558LEVFF

Bali Muralidhar

Born 1979. Board Member since 2014. Member of the audit committee.

  • Education: BMBCh in clinical medicine, Oxford University. MA in medical sciences and Ph.D. in cancer biology, Cambridge University.
  • Other current assignments: Board member of Onbone Oy, AP Brands and Zipline Medical Inc. and is observer on the supervisory boards of Providence Medical Technology, Inc. and Valneva SE. Partner with MVM Life Science Partners LLP.
  • Previous assignments (last five years): None.
  • Position: Independent of the Company and executive management. Dependent to major shareholders.
  • Holdings in the Company: None.

Hans Schikan

Hans Schikan

Born 1958. Board Member since 2015. Chairman of the remuneration committee.

  • Education: Pharm.D, Utrecht University.
  • Other current assignments: Chairman of the board of Asceneuron SA, InteRNA Technologies BV and Complix NV. Board member of Swedish Orphan Biovitrum AB (publ), Hansa Medical AB (publ) and Therachon AG. Member of the Top Team of the Dutch Top Sector Life Sciences & Health.
  • Previous assignments (last five years): CEO and board member of Prosensa Holding NV.
  • Position: Independent of the Company, executive management and major shareholders.
  • Holdings in the Company: 170,000 stock options and 16,000 performance shares Board LTIP 2016.

Birgitte Volck

Birgitte Volck

Born 1962. Board Member since 2017.

  • Education: MD and PhD Copenhagen University.
  • Other current assignments: Senior Vice president, Head of R&D rare Disease at GlaxoSmithKline. Boarmember of TFS Trial Form Support International AB and Ascendis Pharma A/S.
  • Previous assignments (last five years): Chief Medical Officer Swedish Orphan Biovitrum AB.
  • Position: Independent of the Company, executive management and major shareholders.
  • Holdings in the Company: None.

Björn Odlander

Björn Odlander

Born 1958. Board Member since 2017. Member of the remuneration committee.

  • Education: MD and PhD Karolinska Insitutet.
  • Other current assignments: Chairman of the board of HealthCap AB. Board member and CEO for Odlander, Fredrikson & Co AB. Board member of NVC Holding AB, Oncorena AB and Bone Support AB.
  • Position: Independent of the Company and executive management. Dependent to major shareholders.
  • Holdings in the Company: –